NanoViricides, Inc. entered into a Securities Purchase Agreement on July 24, 2026, for a registered direct offering that closed on July 27, 2026. The company sold 2,416,339 shares of common stock at $1.53 per share and pre-funded warrants to purchase 100,000 additional shares at $1.52999 each. Accompanying these instruments are common warrants to purchase up to 2,516,339 shares exercisable at $1.75 per share, expiring five and a half years from issuance. The offering generated approximately $3.8 million in gross proceeds before placement agent fees and expenses. D. Boral Capital LLC served as the exclusive placement agent, receiving a 7.0% cash fee plus up to $50,000 in reimbursed expenses. Lock-up agreements were executed by CEO Anil Diwan and principal stockholder TheraCour Pharma, Inc., restricting sales for 30 days post-closing. The company intends to use net proceeds for working capital, research and development, clinical trials, and strategic acquisitions. NanoViricides is a clinical-stage biotechnology company developing broad-spectrum antivirals based on host-mimetic nanomedicine technology.

NanoViricides, Inc. entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC on July 17, 2026, allowing the company to offer and sell common stock through an at-the-market offering. The company will pay a 2.0% commission to the Sales Agent for each sale of shares. NanoViricides, Inc. is a biotechnology company focused on developing antiviral-based therapeutics.